Finally, IL-17 inhibitors increased risks of atherosclerosis (aHR, 3.70; 95% CI, 1.14–11.97) and COPD (aHR, 2.96; 95% CI, 1.08–8.14) but reduced those of herpes zoster (aHR, 0.49; 95% CI, 0.25–0.99) and mood disorder risks (aHR, 0.23; 95% CI, 0.06–0.94). Here, IL17A is linked to chronic obstructive pulmonary disease.